UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 27, 2004

MEDTOX SCIENTIFIC, INC.
(Exact name of registrant as specified in its charter)

Delaware	1-11394	95-3863205
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of incorporation)		Identification No.)

402 West County Road D, St. Paul, Minnesota	55112
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (651) 636-7466

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01.    Entry into a Material Definitive Agreement

On September 27, 2004, MEDTOX Scientific, Inc., MEDTOX Laboratories, Inc., MEDTOX Diagnostics, Inc. and Consolidated Medical Services, Inc. (collectively referred to as the Company) entered into the Fifth Amendment to the Amended and Restated Credit and Security Agreement (“Fifth Amendment”) with Wells Fargo Business Credit, Inc. (“Lender”). The Fifth Amendment modifies the terms of the Amended and Restated Credit and Security Agreement, dated as of May 7, 2001, but effective as of March 31, 2001, as amended by the First Amendment to the Amended and Restated Credit and Security Agreement, dated as of October 24, 2001, as further amended by the Second Amendment to the Amended and Restated Credit and Security Agreement, dated as of May 1, 2002, as further amended by the Third Amendment to the Amended and Restated Credit and Security Agreement, dated as of August 14, 2003, and as further amended by the Fourth Amendment to the Amended and Restated Credit and Security Agreement, dated as of March 5, 2004. The Fifth Amendment reduces the interest rate on the note for the purchase of capital equipment and increases the maximum amount available for borrowing for the purchase of capital equipment. The Fifth Amendment also provides the lender’s consent to the Company’s payment of all principal and interest on its Subordinated Notes. The Fifth Amendment is filed herewith as Exhibit 10.1 and incorporated herein by reference.

2

Item 9.01.    Financial Statements and Exhibits.

(a) Financial statements of businesses acquired.
Not applicable.

(b) Proforma financial information.
Not applicable.

(c) Exhibits.

        The following exhibit is filed as part of this report:

Exhibit No.	Description
10.1	FIFTH AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT DATED AS OF SEPTEMBER 27, 2004, BY AND AMONG MEDTOX SCIENTIFIC, INC., MEDTOX LABORATORIES, INC., MEDTOX DIAGNOSTICS, INC., CONSOLIDATED MEDICAL SERVICES, INC. AND WELLS FARGO BUSINESS CREDIT, INC

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MEDTOX Scientific, Inc.
Date:   September 27, 2004	By:          /s/ Richard J. Braun
	Name:     Richard J. Braun
	Title:       Chief Executive Officer

4

INDEX TO EXHIBITS

Exhibit No.	Description
10.1	FIFTH AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT DATED AS OF SEPTEMBER 27, 2004, BY AND AMONG MEDTOX SCIENTIFIC, INC., MEDTOX LABORATORIES, INC., MEDTOX DIAGNOSTICS, INC., CONSOLIDATED MEDICAL SERVICES, INC. AND WELLS FARGO BUSINESS CREDIT, INC

5